Estimands in hematologic oncology trials

  title={Estimands in hematologic oncology trials},
  author={Steven Sun and Hans-Jochen Weber and Emily Butler and Kaspar Rufibach and Satrajit Roychoudhury},
  journal={Pharmaceutical Statistics},
  pages={793 - 805}
The estimand framework included in the addendum to the ICH E9 guideline facilitates discussions to ensure alignment between the key question of interest, the analysis, and interpretation. Therapeutic knowledge and drug mechanism play a crucial role in determining the strategy and defining the estimand for clinical trial designs. Clinical trials in patients with hematological malignancies often present unique challenges for trial design due to complexity of treatment options and existence of… 

A simple principal stratum estimator for failure to initiate treatment

It is shown that a simple principal stratum estimator based on a “modified intention-to-treat” population, where participants who experience the intercurrent event are excluded, is unbiased for the principalstratum estimand under certain assumptions that are likely to be plausible in many trials.

Estimands for factorial trials

It is concluded that careful use of the estimands framework clarifies research objectives and reduces the risk of misinterpretation of trial results, and should become a standard part of both the protocol and reporting of factorial trials.

A Review of Causal Inference for External Comparator Arm Studies

This publication aims to provide a methodological overview, to sketch emergent best practice recommendations and to identify future methodological research topics, including sample size considerations, use of estimands, handling of different data sources regarding differential baseline covariate definitions, differential endpoint measurements and timings.



Estimands and the Patient Journey: Addressing the Right Question in Oncology Clinical Trials.

The newly introduced estimand framework is reviewed to structure discussions on the relationship between patient journeys and the treatment effect of interest in oncology trials and is expected to improve coherence between trial objectives, design, analysis, and interpretation.

Estimand Framework in AML Based on a Randomized, Placebo-Controlled, Phase 3 Study Investigating the Effect of Adding Midostaurin to Standard Chemotherapy in Patients with Newly Diagnosed AML without a FLT3 Mutation

EFS is described in the estimand framework to address the scientific question of interest and illustrate the power of this concept to transparently define the relevant population, the variable of interest, and the management of relevant incidents that can occur in a clinical trial ("intercurrent events").

Estimands in clinical trials – broadening the perspective

It is concluded that disentangling adherence to treatment and the efficacy and safety of treatment in patients that adhere leads to a transparent and clinical meaningful assessment of treatment risks and benefits.

Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials—Application of the Estimand Framework

It is argued that the clinical trial objective from a world without COVID-19 pandemic remains valid and the applicability of the estimand framework may even go beyond what it was initially intended for.

Seeking harmony: estimands and sensitivity analyses for confirmatory clinical trials

The resulting “ICH E9/R1” guideline will include a framework for improved trial planning, conduct, analysis, and interpretation; a draft is expected to be ready for public comment in the second half of 2016.

Adjusting overall survival for treatment switches: commonly used methods and practical application

Several commonly used statistical methods are described that try to adjust time‐to‐event data to account for treatment switching, ranging from naive exclusion and censoring approaches to more complex inverse probability of censoring weighting and rank‐preserving structural failure time models.

Choosing Appropriate Estimands in Clinical Trials

This study presents a process chart including all aspects to consider during planning of any clinical trial and recommends that one bear in mind the process chart during planning and give reasonable justification for each decision in the study protocol.

Treatment effect quantification for time‐to‐event endpoints–Estimands, analysis strategies, and beyond

It is suggested that for a large randomized clinical trial how the analyses for the primary and secondary endpoints as well as the analyses actually performed in the trial can be seen in the context of the addendum should be seen.

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

This phase III trial is designed to evaluate whether the addition of elotuzumab to an intensified treatment concept with high dose melphalan chemotherapy plus autologous stem cell transplantation and induction, consolidation and maintenance treatment with bortezomib and lenalidomide is able to improve PFS compared to the same concept without elotzumab.

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

The addition of the multitargeted kinase inhibitor midostaurin to standard chemotherapy significantly prolonged overall and event‐free survival among patients with AML and a FLT3 mutation.